Alibaba Health Information Tech revenue and financials
In the fiscal year ended March 2026, Alibaba Health Information Tech reported revenue of ¥34.26B (+11.95% year over year). Net income was ¥1.94B, a net margin of 5.7%.
Fiscal year ending in March. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +11.95%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +35.17%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 5.7%
- FY to Mar 2025: 4.7%
How Alibaba Health Information Tech is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 17.2% a year on average over the last 5 years
Compound annual growth rate: from ¥15.52B in 2021 to ¥34.26B in 2026.
Revenue has grown for 9 fiscal years in a row
Each fiscal year compared with the one before, up to 2026.
Operating margin rose from −0.2% to 5.3%
Operating income over revenue, 2023 → 2026: 5.5 percentage points.
Free cash flow equal to 86% of net income
Totals for fiscal years 2024–2026: free cash flow ¥3.66B, net income ¥4.25B.
Shares outstanding up 21.6% in 5 years
Average diluted shares, 2021 → 2026: with more shares, each one represents a smaller stake in the company (dilution).
Profitable in 4 of 5 fiscal years
Positive net income, fiscal years 2022–2026.
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 | FY to Mar 2021 | FY to Mar 2020 | FY to Mar 2019 | FY to Mar 2018 | FY to Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 34,255 | 30,598 | 27,027 | 26,763 | 20,578 | 15,518 | 9,596 | 5,096 | 2,443 | 475 |
| Cost of revenue | 26,045 | 23,166 | 21,131 | 21,062 | 16,470 | 11,901 | 7,370 | 3,766 | 1,792 | 288 |
| Gross profit | 8,210 | 7,432 | 5,895 | 5,701 | 4,108 | 3,617 | 2,226 | 1,330 | 650 | 187 |
| Selling, general and administrative | 5,586 | 5,234 | 4,550 | 5,055 | 4,474 | 3,135 | 2,041 | 1,208 | 661 | 276 |
| Research and development | 788 | 720 | 705 | 678 | 729 | 424 | 253 | 219 | 126 | 109 |
| Operating income | 1,829 | 1,454 | 635 | -51.5 | -1,098 | 37.5 | -67.4 | -98.2 | -140 | -202 |
| EBIT | 1,829 | 1,454 | 635 | -51.5 | -1,098 | 37.5 | -67.4 | -98.2 | -140 | -202 |
| EBITDA | 1,859 | 1,486 | 659 | -24.5 | -1,077 | 52.1 | -53.0 | -94.2 | -136 | -198 |
| Interest expense | 1.4 | 2.6 | 6.0 | 5.8 | 3.8 | 2.4 | 21.9 | 28.0 | 10.1 | 6.9 |
| Pre-tax income | 2,274 | 1,560 | 939 | 551 | -253 | 401 | 9.1 | -60.8 | -95.1 | -207 |
| Income tax | 338 | 128 | 56.3 | 14.5 | 13.4 | 58.5 | 24.8 | 30.9 | 13.9 | 1.6 |
| Net income | 1,936 | 1,432 | 883 | 536 | -266 | 349 | -6.6 | -81.9 | -107 | -208 |
| Net income to common shareholders | 1,936 | 1,432 | 883 | 536 | -266 | 349 | -6.6 | -81.9 | -107 | -208 |
| Basic EPS | 0.12 | 0.09 | 0.06 | 0.04 | -0.02 | 0.03 | -0.00 | -0.01 | -0.01 | -0.03 |
| Diluted EPS | 0.12 | 0.09 | 0.06 | 0.04 | -0.02 | 0.03 | -0.00 | -0.01 | -0.01 | -0.03 |
| Average shares (basic) | 16,110 | 16,071 | 14,044 | 13,503 | 13,483 | 13,246 | 11,931 | 11,055 | 9,188 | 8,179 |
| Average shares (diluted) | 16,199 | 16,136 | 14,091 | 13,542 | 13,483 | 13,327 | 11,931 | 11,055 | 9,188 | 8,179 |
| Dividend per share | 0.06 | — | — | — | — | — | — | — | — | — |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q1 2026 | Q3 2025 | Q1 2025 | Q3 2024 | Q1 2024 | Q3 2023 | Q1 2023 | Q3 2022 | Q1 2022 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 17,558 | 16,697 | 16,325 | 14,274 | 14,071 | 12,956 | 15,262 | 11,501 | 11,220 | 9,358 |
| Cost of revenue | 13,532 | 12,513 | 12,426 | 10,740 | 11,044 | 10,087 | 11,862 | 9,200 | 8,983 | 7,487 |
| Gross profit | 4,026 | 4,184 | 3,898 | 3,534 | 3,027 | 2,869 | 3,401 | 2,301 | 2,237 | 1,871 |
| Selling, general and administrative | 2,841 | 2,744 | 2,804 | 2,429 | 2,262 | 2,288 | 3,049 | 2,007 | 2,340 | 2,134 |
| Research and development | 475 | 313 | 401 | 319 | 386 | 319 | 354 | 324 | 406 | 323 |
| Operating income | 711 | 1,117 | 681 | 772 | 375 | 260 | -13.4 | -38.1 | -507 | -591 |
| EBIT | 711 | 1,117 | 681 | 772 | 375 | 260 | -13.4 | -38.1 | -507 | -591 |
| EBITDA | 726 | 1,133 | 700 | 786 | 387 | 272 | -0.6 | -23.9 | -491 | -586 |
| Interest expense | 0.7 | 0.7 | 1.1 | 1.5 | 3.5 | 2.5 | 2.5 | 3.4 | 3.1 | 0.7 |
| Pre-tax income | 845 | 1,429 | 739 | 821 | 458 | 481 | 377 | 174 | -22.7 | -230 |
| Income tax | 175 | 163 | 75.9 | 52.0 | 20.1 | 36.1 | 4.0 | 10.5 | 11.7 | 1.7 |
| Net income | 670 | 1,267 | 663 | 769 | 438 | 446 | 373 | 162 | -33.8 | -232 |
| Net income to common shareholders | 670 | 1,267 | 663 | 769 | 438 | 446 | 373 | 162 | -33.8 | -232 |
| Basic EPS | 0.04 | 0.08 | 0.04 | 0.05 | 0.03 | 0.03 | 0.03 | 0.01 | -0.00 | -0.02 |
| Diluted EPS | 0.04 | 0.08 | 0.04 | 0.05 | 0.03 | 0.03 | 0.03 | 0.01 | -0.00 | -0.02 |
| Average shares (basic) | 16,100 | 16,121 | 16,076 | 16,065 | 14,575 | 13,513 | 13,497 | 13,509 | 13,487 | 13,478 |
| Average shares (diluted) | 16,196 | 16,202 | 16,175 | 16,097 | 14,629 | 13,552 | 13,562 | 13,521 | 13,487 | 13,478 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 | FY to Mar 2021 | FY to Mar 2020 | FY to Mar 2019 | FY to Mar 2018 | FY to Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 23,093 | 21,178 | 19,705 | 20,748 | 19,202 | 17,739 | 7,870 | 5,982 | 3,111 | 1,680 |
| Current assets | 15,422 | 12,276 | 13,512 | 14,914 | 13,566 | 14,200 | 5,013 | 3,303 | 2,016 | 811 |
| Cash and equivalents | 5,434 | 2,218 | 3,490 | 10,917 | 10,548 | 11,637 | 2,595 | 280 | 1,397 | 570 |
| Short-term investments | 4,431 | 5,618 | 6,063 | — | — | — | — | — | — | 19.6 |
| Receivables | 2,448 | 2,073 | 1,911 | 1,279 | 1,074 | 773 | 589 | 539 | 144 | 38.5 |
| Inventory | 1,849 | 1,415 | 1,400 | 2,102 | 1,550 | 1,469 | 1,217 | 596 | 442 | 152 |
| Net property, plant and equipment | 87.6 | 69.7 | 104 | 68.5 | 165 | 52.3 | 82.9 | 8.9 | 6.3 | 5.1 |
| Goodwill | 805 | 811 | 811 | 811 | 811 | 54.6 | 54.6 | 27.0 | 19.1 | 19.1 |
| Other intangible assets | 258 | 275 | 292 | 309 | 326 | 2.9 | 4.5 | — | — | — |
| Long-term investments | 6,364 | 7,602 | 4,900 | 4,591 | 4,297 | 3,412 | 2,686 | 2,553 | 1,014 | 567 |
| Current liabilities | 5,093 | 4,742 | 5,025 | 5,437 | 4,822 | 3,401 | 2,610 | 3,233 | 580 | 353 |
| Accounts payable | 3,030 | 2,852 | 3,351 | 3,714 | 3,529 | 2,552 | 1,866 | 903 | 323 | 126 |
| Long-term debt | — | — | — | — | — | — | — | — | — | 200 |
| Total debt | 59.8 | 35.5 | 82.2 | 77.8 | 135 | 37.7 | 69.8 | — | — | 200 |
| Total liabilities | 5,237 | 4,865 | 5,188 | 5,601 | 5,130 | 3,458 | 2,667 | 3,245 | 588 | 560 |
| Total equity (incl. minority) | 17,857 | 16,313 | 14,518 | 15,147 | 14,072 | 14,282 | 5,203 | 2,737 | 2,523 | 1,120 |
| Retained earnings | 3,149 | 1,324 | -12.0 | -842 | -1,309 | -986 | -1,297 | -1,281 | -1,190 | -1,092 |
| Minority interest | 1.2 | 1.0 | -26.6 | -26.4 | -26.2 | -20.3 | -66.6 | -57.7 | -57.2 | -58.2 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q1 2026 | Q3 2025 | Q1 2025 | Q3 2024 | Q1 2024 | Q3 2023 | Q1 2023 | Q3 2022 | Q1 2022 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 23,093 | 23,265 | 21,178 | 20,269 | 19,705 | 21,440 | 20,748 | 20,322 | 19,202 | 19,658 |
| Current assets | 15,422 | 15,024 | 12,276 | 11,914 | 13,512 | 15,682 | 14,914 | 14,576 | 13,566 | 14,626 |
| Cash and equivalents | 5,434 | 4,935 | 2,218 | 7,443 | 3,490 | 11,697 | 10,917 | 11,255 | 10,548 | 11,256 |
| Short-term investments | 4,431 | 4,432 | 5,618 | — | 6,063 | — | — | — | — | — |
| Receivables | 2,448 | 1,305 | 2,073 | 843 | 1,911 | 607 | 1,279 | 533 | 1,074 | 505 |
| Inventory | 1,849 | 2,071 | 1,415 | 1,634 | 1,400 | 1,727 | 2,102 | 1,609 | 1,550 | 1,760 |
| Net property, plant and equipment | 87.6 | 109 | 69.7 | 90.3 | 104 | 106 | 68.5 | 79.5 | 165 | 93.8 |
| Goodwill | 805 | 811 | 811 | 811 | 811 | 811 | 811 | 811 | 811 | 845 |
| Other intangible assets | 258 | 267 | 275 | 284 | 292 | 301 | 309 | 317 | 326 | 336 |
| Long-term investments | 6,364 | 6,859 | 7,602 | 7,108 | 4,900 | 4,493 | 4,591 | 4,499 | 4,297 | 3,747 |
| Current liabilities | 5,093 | 5,541 | 4,742 | 4,870 | 5,025 | 5,210 | 5,437 | 5,229 | 4,822 | 5,352 |
| Accounts payable | 3,030 | 3,581 | 2,852 | 3,037 | 3,351 | 3,459 | 3,714 | 3,750 | 3,529 | 4,234 |
| Total debt | 59.8 | 75.9 | 35.5 | 68.1 | 82.2 | 88.2 | 77.8 | 88.2 | 135 | 67.8 |
| Total liabilities | 5,237 | 5,698 | 4,865 | 5,019 | 5,188 | 5,378 | 5,601 | 5,404 | 5,130 | 5,610 |
| Total equity (incl. minority) | 17,857 | 17,567 | 16,313 | 15,249 | 14,518 | 16,062 | 15,147 | 14,918 | 14,072 | 14,048 |
| Retained earnings | 3,149 | 2,479 | 1,324 | 702 | -12.0 | -440 | -842 | -1,192 | -1,309 | -1,219 |
| Minority interest | 1.2 | 0.8 | 1.0 | -26.5 | -26.6 | -27.0 | -26.4 | -25.8 | -26.2 | -25.6 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 | FY to Mar 2021 | FY to Mar 2020 | FY to Mar 2019 | FY to Mar 2018 | FY to Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1,237 | 1,395 | 1,080 | 256 | 424 | 1,009 | 584 | 396 | -70.3 | -226 |
| Depreciation and amortization | 53.2 | 57.6 | 53.7 | 63.7 | 60.6 | 39.6 | 41.7 | 4.0 | 4.5 | 4.6 |
| Capital expenditure | -9.0 | -18.9 | -22.8 | -5.6 | -14.9 | -17.1 | -7.6 | -6.1 | -5.7 | -2.1 |
| Investing cash flow | 2,021 | -2,596 | -4,881 | -532 | 1,872 | -4,961 | 1,345 | -2,396 | -1,211 | -159 |
| Financing cash flow | -14.2 | -72.5 | -1,982 | -111 | -58.6 | 8,922 | 329 | 1,708 | 1,248 | 193 |
| Share repurchases | 0.0 | -39.9 | -105 | -81.6 | -16.5 | -39.6 | -17.8 | -37.8 | -13.1 | — |
| Debt issued | — | — | — | — | — | — | — | 2,304 | 596 | 200 |
| Debt repaid | -25.0 | -38.1 | -39.9 | -42.6 | -47.0 | -31.6 | -1,730 | -604 | -796 | -0.7 |
| Effect of exchange rates | -27.6 | 2.1 | 36.8 | 283 | -149 | -313 | 56.8 | 62.8 | -28.5 | 47.6 |
| Net change in cash | 3,216 | -1,272 | -5,747 | -105 | 2,089 | 4,657 | 2,315 | -228 | -61.4 | -145 |
| Free cash flow | 1,228 | 1,376 | 1,057 | 250 | 409 | — | — | — | — | — |
| Levered free cash flow | 600 | 693 | 319 | -19.6 | 701 | 696 | 565 | 418 | -149 | -68.1 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q1 2026 | Q3 2025 | Q1 2025 | Q3 2024 | Q1 2024 | Q3 2023 | Q1 2023 | Q3 2022 | Q1 2022 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 673 | 563 | 833 | 562 | 170 | 910 | -248 | 504 | -173 | 598 |
| Depreciation and amortization | 29.7 | 23.6 | 31.2 | 26.4 | 28.5 | 25.2 | 27.8 | 35.9 | 37.5 | 23.1 |
| Capital expenditure | -3.0 | -6.0 | -15.8 | -3.1 | -6.3 | -16.5 | -0.9 | -4.8 | -8.2 | -6.8 |
| Investing cash flow | -196 | 2,217 | -1,863 | -734 | -3,901 | -979 | 204 | -737 | 531 | 1,341 |
| Financing cash flow | -12.6 | -1.7 | -33.8 | -38.7 | -1,952 | -30.1 | -95.3 | -16.0 | -37.8 | -20.8 |
| Share repurchases | — | — | -17.0 | -22.9 | -91.0 | -13.6 | -81.6 | — | -16.5 | — |
| Debt repaid | -15.3 | -9.7 | -22.0 | -16.1 | -23.2 | -16.7 | -18.4 | -24.2 | -24.8 | -22.2 |
| Effect of exchange rates | 34.4 | -62.0 | 52.8 | -50.7 | -146 | 183 | -26.5 | 310 | -25.0 | -124 |
| Net change in cash | 499 | 2,717 | -1,011 | -261 | -5,831 | 83.8 | -166 | 61.4 | 295 | 1,794 |
| Free cash flow | 670 | 557 | 817 | 559 | 163 | 894 | -249 | 499 | -181 | 591 |
| Levered free cash flow | 462 | 138 | 434 | 259 | -198 | 517 | -298 | 278 | -295 | 996 |
Financial statements of similar companies
Companies in the group: same and related industries, similar size
